A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

Condition:   Follicular Lymphoma Interventions:   Drug: Axicabtagene Ciloleucel;   Drug: Cyclophosphamide;   Drug: Fludarabine phosphate;   Drug: Prednisone;   Drug: Diphenhydramine;   Drug: Acetaminophen Sponsor:   M.D. Anderson Cancer Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials